Pharmaceutical preparation
AssigneeAposcience AG
InventorHendrik Jan Ankersmit
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical preparation for treating an inflammatory condition, preferably a condition associated with ischemia comprising: a) a physiological solution comprising peripheral blood mononuclear cells (PBM-Cs) or a subset thereof, or b) a supernatant of the solution a), wherein the solution a) is obtainable by cultivating PBMCs or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.
Claims20
A pharmaceutical preparation, comprising a dosage form of a cell-free culture supernatant of peripheral blood mononuclear cells (PBMCs), the cell-free culture supernatant comprising at least 2000 pg/mL of matrix metallopeptidase 9 (MMP-9) and no detectable amount of TNF-α, the PBMCs comprising non-activated, non-proliferating T cells, B cells, NK cells, and monocytes cultivated under a stress inducing condition comprising a dose of at least 10 Gy radiation in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.
A pharmaceutical preparation, comprising a dosage form of a culture supernatant of peripheral blood mononuclear cells (PBMCs) free of cells other than the PBMCs, the supernatant comprising at least 2000 pg/ml of matrix metallopeptidase 9 (MMP-9) and no detectable amount of TNF-α and INF-γ, wherein the PBMCs are selected from non-activated, non-proliferating T cells, B cells, NK cells, and monocytes cultivated in vitro under a stress inducing condition comprising a dose of at least 10 Gy radiation and in a physiological solution free of PBMC-proliferating and PBMC-activating substances for least 1 h, wherein the culture supernatant PBMC optionally contains PBMCs.
A pharmaceutical preparation, comprising a dosage form of a culture supernatant having no detectable amount of TNF-α, the culture supernatant being produced by in vitro cultivation of peripheral blood mononuclear cells (PBMCs) exposed to at least 10 Gy γ-radiation in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h, the PBMCs being separated from whole blood and consisting of T cells, B cells, NK cells, and monocytes.
Dependencies are inferred from the claim text.